The new installation of Philips Lung Suite’s real-time 3D imaging solution in Belgium, France, Israel and the UK highlights the growing interest in the company’s integrated lung cancer diagnosis and treatment solution

The Philips Lung Suite enables precise diagnosis and minimally invasive therapy in one room

The first clinical trial of a minimally invasive procedure using a Philips solution begins with the first success story

AMSTERDAM, March 28th.

Royal Philipsa world leader in health technology, has announced that its innovative solutions for the diagnosis and treatment of lung cancerPhilips Lung Suite– has been adopted by a new clinical partner. Among the clinical centers that have chosen this solution are: Royal Brompton Hospital from London, Hospital Abolition from Brussels, Medical Center East Limburg Hospital (ZOL) from Genk (Belgium), the Carmel Medical Center from Haifa (Israel). That Rouen University Hospital (France) is also planning to start using Philips solutions and several healthcare providers have successfully diagnosed their first patients using the Lung Suite, which works in combination with the company’s image-guided therapy system, Azurion.

Lung cancer is the leading cause of cancer death worldwide, claiming the lives of 1.8 million people every year. [1]. More than 60% of lung cancer patients are diagnosed at an advanced stage, reducing their chances of survival [2]. The Philips Lung Suite is a revolutionary real-time 3D imaging platform that addresses the need for pre-precision diagnosis and minimally invasive treatment with an all-in-one platform that allows doctors to perform biopsies, ablations, injury markings and thoracic surgeries at the same time. room. Its ability to find and characterize small lesions could significantly improve lung cancer treatments in the future.

“We have shown that the Philips Lung Suite improves the accuracy of lung cancer biopsy procedures, provides better patient outcomes and the potential to treat patients immediately when cancer is at an early stage,” said Karim Boussebaa, CEO of Philips Image Guided Therapy Systems. “This new partner adds to our global ecosystem of clinical partners driving innovation with the goal of offering patients minimally invasive diagnosis and treatment in a single procedure, improving patient outcomes and quality of life.” .

Pictures without hidden nodules

The Philips Lung Suite offers advanced real-time 3D imaging with additional fluoroscopy in an image-guided therapy system combined with special software. With Philips Cone Beam CT, the X-ray detector rotates around the patient to produce a CT-like image in about five seconds, providing doctors with a high-resolution 3D view of the target lesion and other anatomical structures. This allows the physician performing the biopsy procedure to be continuously guided by high-quality real-time images to insert the catheter into the lesion through the bronchoscope. Once this is done, its position can be confirmed in real time using the same imaging modality and a biopsy sample can be taken.

“In the rapidly evolving world of intraoperative imaging, cone beam CT remains the gold standard for additional fluoroscopy and lesion confirmation. With the Lung Suite, no nodule can be hidden, regardless of anatomic position.” or radiological characteristics, which make them valuable tools for diagnosis and future ablation procedures,” explains Dr. Amir Abramovich, Director of Interventional Pulmonology at Haifa Carmel Medical Center in Israel.

“Cone beam CT is an important step in detecting nodules smaller than 20mm and an important tool for the transition to bronchoscopy microwave ablation of peripheral lung lesions,” said Professor Shah Pallav, pulmonologist at Royal Hospital, London Brompton.

“Combining the advanced imaging of cone-beam CT with magnified fluoroscopy from the Philips Lung Suite gave us the confidence to safely biopsy hard-to-reach peripheral lung nodules,” added Dr. Maarten Criel, Pulmonologist at ZOL Doctor Center from Genk.

Dr Kelvin Lau, Consultant and Principal Thoracic Surgeon at St Bartholomew’s Hospital, London, has successfully diagnosed and treated lung cancer patients using cone beam CT for biopsies, bronchoscopy microwave ablation and precision-guided surgery. clinical trials. The advanced imaging provided by the Philips Lung Suite is used during this procedure for real-time 3D imaging guidance and confirmation of results. Philips expects similar clinical trials to begin in other hospitals around the world soon.

One Article published in October 2021 in the Journal of Bronchology & Interventional Pulmonology, authored by researchers at Radboud University Medical Center, Netherlands, demonstrates the diagnostic potential of the Lung Suite. The investigators succeeded in increasing the diagnostic accuracy of navigational bronchoscopy from 72% to 90%. In addition, the average total effective radiation dose per procedure is more than half. [3].

Reference:

[1] https://www.who.int/news-room/fact-sheets/detail/cancer

[2] https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html

[3] Journal of Bronchology & Interventional Pulmonology: October 2021 – Volume 28 – Issue 4 – p 262-271 doi: 10.1097/LBR.0000000000000783

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHI) is a leading healthcare technology company focused on improving people’s lives and facilitating better outcomes across the health continuum, from healthy behavior and prevention to diagnosis, treatment and home care. Philips uses its advanced technology and deep clinical and consumer insights to provide integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, health monitoring and informatics, and consumer health and home care. Philips posted revenues of €17.2 billion in 2021 and employs approximately 78,000 people, with business and service operations in more than 100 countries. All Philips news is in www.philips.es/prensa

Emission: Royal Philips

Contact: César García Requena, Brand & Communications Manager, Philips Ibérica. Phone 670 264471, email cesar.garcia.requena@philips.com